- Home
- CING vs BIAF Comparison
CING vs BIAF Comparison
Compare CING & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- BIAF
- Stock Information
- Founded
- CING 2012
- BIAF 2014
- Country
- CING United States
- BIAF United States
- Employees
- CING N/A
- BIAF N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CING Health Care
- BIAF Health Care
- Exchange
- CING Nasdaq
- BIAF Nasdaq
- Market Cap
- CING 14.4M
- BIAF 12.2M
- IPO Year
- CING 2021
- BIAF 2022
- Fundamental
- Price
- CING $4.27
- BIAF $0.83
- Analyst Decision
- CING Strong Buy
- BIAF Strong Buy
- Analyst Count
- CING 3
- BIAF 1
- Target Price
- CING $16.00
- BIAF $6.00
- AVG Volume (30 Days)
- CING 118.1K
- BIAF 76.9K
- Earning Date
- CING 03-31-2025
- BIAF 03-31-2025
- Dividend Yield
- CING N/A
- BIAF N/A
- EPS Growth
- CING N/A
- BIAF N/A
- EPS
- CING N/A
- BIAF N/A
- Revenue
- CING N/A
- BIAF $9,367,785.00
- Revenue This Year
- CING N/A
- BIAF $285.51
- Revenue Next Year
- CING N/A
- BIAF $20.05
- P/E Ratio
- CING N/A
- BIAF N/A
- Revenue Growth
- CING N/A
- BIAF 2813.87
- 52 Week Low
- CING $1.80
- BIAF $0.57
- 52 Week High
- CING $20.83
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- CING 42.05
- BIAF 52.41
- Support Level
- CING $4.22
- BIAF $0.75
- Resistance Level
- CING $4.58
- BIAF $0.85
- Average True Range (ATR)
- CING 0.32
- BIAF 0.06
- MACD
- CING -0.04
- BIAF 0.01
- Stochastic Oscillator
- CING 12.64
- BIAF 87.18
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.